Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial.
Expert opinion on drug safety（2022）
摘要
ClinicalTrials.gov: NCT03962738.
更多查看译文
关键词
Cardiovascular risk factors,Japan,headache,lasmiditan,migraine disorders,safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要